Literature DB >> 25534441

Enhanced microglial activity in FAAH(-/-) animals.

F Ativie1, O Albayram1, K Bach1, B Pradier1, A Zimmer1, A Bilkei-Gorzo2.   

Abstract

AIMS: Several lines of evidence suggest that the endocannabinoid system is involved in the regulation of glial activity. Enhanced levels of the endocannabinoid N-arachidonoyl ethanolamine (AEA, also referred to as anandamide) as well as non-cannabinoid lipids like palmitoylethanolamine (PEA) due to genetic deletion or pharmacologic blockade of its degrading enzyme fatty acid amide hydrolase (FAAH) reduced neuroinflammatory changes in models of neurodegeneration. Now we addressed the question if genetic deletion of FAAH also influences age-related neuroinflammation. MAIN
METHODS: To answer this question we compared the number and size of microglia in young and old wild-type and FAAH(-/-) mice and analysed the distribution of microglia sizes in the four groups. Additionally, we analysed IL-6 and IL-1β levels with ELISA and astrocyte activities as ratio of GFAP-positive areas in the hippocampus. KEY
FINDINGS: Ageing was associated with an increased number and activity of microglia, elevated IL-6 and IL-1β levels and enhanced area covered by astrocytes in wild-type animals. Unexpectedly, in FAAH(-/-) animals the number of microglia and the ratio of activated microglia and IL-1β level were already higher in young animals than in age-matched wild-type controls. There was no further age-related increase in these inflammation markers in the knockout line. SIGNIFICANCE: Our results suggest that AEA is involved in the regulation of microglia activity. Life-long elevation of AEA levels disturbs microglial regulation and leads to pro-inflammatory changes.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ageing; Anandamide; Astrocyte; FAAH; Microglia; Neuroinflammation

Mesh:

Substances:

Year:  2014        PMID: 25534441     DOI: 10.1016/j.lfs.2014.12.016

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

Review 1.  CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease.

Authors:  Ester Aso; Isidro Ferrer
Journal:  Front Neurosci       Date:  2016-05-31       Impact factor: 4.677

2.  Cannabinoid 1 receptor signaling on GABAergic neurons influences astrocytes in the ageing brain.

Authors:  Andras Bilkei-Gorzo; Onder Albayram; Frank Ativie; Safak Chasan; Till Zimmer; Karsten Bach; Andreas Zimmer
Journal:  PLoS One       Date:  2018-08-16       Impact factor: 3.240

3.  Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer's Disease in a Preclinical Model: A Therapeutic Opportunity.

Authors:  Dina Medina-Vera; Cristina Rosell-Valle; Antonio J López-Gambero; Juan A Navarro; Emma N Zambrana-Infantes; Patricia Rivera; Luis J Santín; Juan Suarez; Fernando Rodríguez de Fonseca
Journal:  Biology (Basel)       Date:  2020-11-05

Review 4.  Microglial Endocannabinoid Signalling in AD.

Authors:  Lucia Scipioni; Francesca Ciaramellano; Veronica Carnicelli; Alessandro Leuti; Anna Rita Lizzi; Noemi De Dominicis; Sergio Oddi; Mauro Maccarrone
Journal:  Cells       Date:  2022-04-06       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.